Earlier Today, GSK Announced Headline Results Of A Phase 2 Trial For Its MRNA Seasonal Influenza Vaccine Program, Demonstrating A And B Strain Immune Responses Relative To Standard Of Care In Both Younger And Older Adults
Earlier Today, GSK Announced Headline Results Of A Phase 2 Trial For Its MRNA Seasonal Influenza Vaccine Program, Demonstrating A And B Strain Immune Responses Relative To Standard Of Care In Both Younger And Older Adults
今天早些時候，GSk宣佈其MRNA季節性流感疫苗計劃的2期試驗的頭條結果，表明相對於標準護理，無論是年輕人還是老年人，都顯示出對A和B株系的免疫反應
Earlier Today, GSK Announced Headline Results Of A Phase 2 Trial For Its MRNA Seasonal Influenza Vaccine Program, Demonstrating A And B Strain Immune Responses Relative To Standard Of Care In Both Younger And Older Adults
今天早些時候，葛蘭素史克公佈了其MRNA季節性流感疫苗計劃2期試驗的總體結果，顯示了與年輕人和老年人標準護理相關的A和b菌株免疫反應
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間